Merck’s MK-7243 Significantly Reduced Allergy Symptoms in Adults and Children in Pivotal Phase III Study

Merck’s MK-7243 Significantly Reduced Allergy Symptoms in Adults and Children in Pivotal Phase III Study

Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced data for its investigational Timothy grass sublingual
allergy immunotherapy tablet (MK-7243) from a study involving 1,501
North American adult and pediatric patients. Results showed that MK-7243
demonstrated significant improvement in Total Combined Score (TCS)
averaged over the entire grass pollen season (the primary endpoint),
which was the sum of the rhinoconjunctivitis daily symptom score (DSS)
and the daily medication score (DMS), compared to placebo. Researchers
will present findings at the American College of Allergy, Asthma &
Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore.

“Patients in this study who took the investigational Timothy grass
sublingual allergy immunotherapy tablet showed a

See full press release

Posted-In: News Guidance Contracts FDA Management Global


Benzinga – Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals


Uncategorized

Leave a Reply

Your email address will not be published.